| Literature DB >> 27941632 |
Qingsen Shang1,2, Qinying Li3,4, Meifang Zhang5,6, Guanrui Song7,8, Jingjing Shi9,10, Hao Jiang11,12, Chao Cai13,14, Jiejie Hao15,16, Guoyun Li17,18, Guangli Yu19,20,21.
Abstract
Keratan sulfate (KS) represents an important family of glycosaminoglycans that are critical in diverse physiological processes. Recently, accumulating evidence has provided a wealth of information on the bioactivity of KS, which established it as an attractive candidate for drug development. However, although KS has been widely explored, less attention has been given to its effect on gut microbiota. Therefore, given that gut microbiota plays a pivotal role in health homeostasis and disease pathogenesis, we investigated here in detail the effect of KS on gut microbiota by high-throughput sequencing. As revealed by heatmap and principal component analysis, the mice gut microbiota was readily altered at different taxonomic levels by intake of low (8 mg/kg) and high dosage (40 mg/kg) of KS. Interestingly, KS exerted a differing effect on male and female microbiota. Specifically, KS induced a much more drastic increase in the abundance of Lactobacillus spp. in female (sixteen-fold) versus male mice (two-fold). In addition, combined with alterations in gut microbiota, KS also significantly reduced body weight while maintaining normal gut homeostasis. Altogether, we first demonstrated a sex-dependent effect of KS on gut microbiota and highlighted that it may be used as a novel prebiotic for disease management.Entities:
Keywords: Lactobacillus spp.; gut microbiota; keratan sulfate; modulation; shark cartilage
Mesh:
Substances:
Year: 2016 PMID: 27941632 PMCID: PMC5192461 DOI: 10.3390/md14120224
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Diversity of gut microbiota in control and KS-treated mice.
| Groups | Reads | OTUs | Good’s Coverage | Richness Estimator | Diversity Estimator | ||
|---|---|---|---|---|---|---|---|
| Ace | Chao1 | Shannon Indices | Simpson Indices | ||||
| KSNF | 19719 | 247 | 0.999036 | 256 | 256 | 4.39 | 0.0201 |
| KSLF | 18384 | 248 | 0.998749 | 260 | 262 | 4.24 | 0.0280 |
| KSHF | 25456 | 263 | 0.999568 | 268 | 266 | 4.45 | 0.0220 |
| KSNM | 28432 | 254 | 0.999402 | 262 | 263 | 4.45 | 0.0188 |
| KSLM | 24572 | 255 | 0.999390 | 262 | 268 | 4.42 | 0.0227 |
| KSHM | 32141 | 258 | 0.999720 | 261 | 261 | 4.41 | 0.0209 |
Abbreviations: female control group (KSNF), female low-dosage group (KSLF), female high-dosage group (KSHF), male control group (KSNM), male low-dosage group (KSLM), and male high-dosage group (KSHM).
Figure 1Response of the gut microbiota to KS treatment. Venn diagram representation of shared/unique OTUs in the gut microbiota of male (A) and female (B) mice; PCA score plot of the gut microbiota in all mice groups (C); 3D-PCoA of the gut microbiota-based weighted UniFrac metric (D).
Figure 2Heatmap demonstrating relative abundance of the dominant bacterial phyla in male (A) and female (B) groups.
Figure 3Heatmap indicating genus-level changes of the gut microbiota in male mice after KS treatment.
Figure 4Heatmap indicating genus-level changes of the gut microbiota in female mice after KS treatment.
Figure 5Oral intake of KS remarkably increased the abundance of Lactobacillus spp. in male (A) and female mice (B).
Figure 6Body weight and serum LBP levels of male (A,B) and female (C,D) mice groups. The results are shown as the mean ± standard deviation. * p < 0.05 versus the control group.